Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd

Bullboard Posts

Comment by threefiftynineon May 30, 2020 12:22pm

86 Views

Post# 31091858

RE:-----GOVERNMENT FUNDING IN PLACE---

if indeed funding is in pace then why a pp with dilution?---and once again if funding is in place then that is material news imo---interesting week coming up imo and Fridays small uptick may well be an indicator---maybe the ceo is a "dark horse" ---time will tell

Bullboard Posts

Fortuna reports record earnings for Q3 2024